Nabriva Therapeutics (NASDAQ:NBRV) Downgraded by Zacks Investment Research

Share on StockTwits

Zacks Investment Research lowered shares of Nabriva Therapeutics (NASDAQ:NBRV) from a buy rating to a hold rating in a research report sent to investors on Thursday morning, Zacks.com reports.

According to Zacks, “Nabriva Therapeutics is a biopharmaceutical company engaged in the research and development of new medicines to treat serious bacterial infections, with a focus on the pleuromutilin class of antibiotics. Nabriva Therapeutics’ medicinal chemistry expertise has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations. Nabriva Therapeutics’ lead product candidate, lefamulin, is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. The company believes that lefamulin is the first antibiotic with a novel mechanism of action to have reached late-stage clinical development in more than a decade. Nabriva has announced positive topline data for lefamulin from the first of its two global, registrational Phase 3 clinical trials evaluating lefamulin in patients with moderate to severe community-acquired bacterial pneumonia (CABP). “

Other analysts have also recently issued reports about the stock. BidaskClub cut shares of Zebra Technologies from a hold rating to a sell rating in a report on Friday, May 24th. ValuEngine cut shares of Zosano Pharma from a buy rating to a hold rating in a report on Wednesday, May 1st. Gabelli reaffirmed a buy rating on shares of Flushing Financial in a report on Thursday, May 2nd. Needham & Company LLC reaffirmed a buy rating and issued a $10.00 price target (down from $15.00) on shares of Nabriva Therapeutics in a report on Wednesday, May 1st. Finally, Northland Securities set a $13.00 price target on shares of Nabriva Therapeutics and gave the company a buy rating in a report on Wednesday, May 8th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company’s stock. Nabriva Therapeutics presently has a consensus rating of Buy and a consensus target price of $7.34.

NBRV opened at $2.42 on Thursday. The company has a fifty day moving average of $2.24. The company has a debt-to-equity ratio of 0.40, a quick ratio of 5.55 and a current ratio of 5.55. Nabriva Therapeutics has a 12-month low of $1.12 and a 12-month high of $3.62.

Nabriva Therapeutics (NASDAQ:NBRV) last posted its quarterly earnings results on Friday, May 10th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.03. The firm had revenue of $1.70 million for the quarter, compared to analysts’ expectations of $0.56 million. Nabriva Therapeutics had a negative net margin of 3,194.72% and a negative return on equity of 119.75%. As a group, equities research analysts anticipate that Nabriva Therapeutics will post -1.14 EPS for the current fiscal year.

Several large investors have recently modified their holdings of the business. Jane Street Group LLC acquired a new stake in shares of Nabriva Therapeutics during the fourth quarter worth $29,000. HRT Financial LLC acquired a new stake in shares of Nabriva Therapeutics during the fourth quarter worth $31,000. Two Sigma Advisers LP acquired a new stake in shares of Nabriva Therapeutics during the fourth quarter worth $37,000. Paloma Partners Management Co acquired a new stake in shares of Nabriva Therapeutics during the fourth quarter worth $54,000. Finally, Fosun International Ltd acquired a new stake in shares of Nabriva Therapeutics during the first quarter worth $1,593,000. 4.18% of the stock is currently owned by institutional investors.

Nabriva Therapeutics Company Profile

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.

Featured Story: What are the benefits of a portfolio tracker?

Get a free copy of the Zacks research report on Nabriva Therapeutics (NBRV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Nabriva Therapeutics (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Jones Lang LaSalle  Earns Buy Rating from Analysts at DA Davidson
Jones Lang LaSalle Earns Buy Rating from Analysts at DA Davidson
Mersana Therapeutics  Upgraded at Zacks Investment Research
Mersana Therapeutics Upgraded at Zacks Investment Research
Nabriva Therapeutics  Downgraded by Zacks Investment Research
Nabriva Therapeutics Downgraded by Zacks Investment Research
Northern Oil and Gas  Lowered to Sell at BidaskClub
Northern Oil and Gas Lowered to Sell at BidaskClub
Neovasc  Upgraded to “Buy” by Zacks Investment Research
Neovasc Upgraded to “Buy” by Zacks Investment Research
Zacks Investment Research Upgrades OptiNose  to “Buy”
Zacks Investment Research Upgrades OptiNose to “Buy”


 
© 2006-2019 Zolmax.